The U.S. Food and Drug Administration has granted approval for Moderna's mRNA-based flu vaccine. This decision marks the first time an mRNA technology has been cleared for a flu shot in the United States.
This approval represents a notable achievement for Moderna, following what sources described as an extensive review process by the regulatory body. The new vaccine introduces a novel approach to influenza prevention.
The move is expected to impact future vaccine development and public health strategies. This is a developing story and will be updated as details emerge.
